Table 2 Pseudomonas aeruginosa (138 strains): results of GDM versus BMD as the reference method
Antibiotic/method | Range | MIC 50 | MIC 90 | Susceptible (%) | Intermediate (%) | Resistant (%) | Kappa | Minor error (%) | Major and very major error (%) |
|---|---|---|---|---|---|---|---|---|---|
Ceftazidime GDM | 0.064- > 256 | 2 | 192 | 102 (73.9) | 13 (9.4) | 23 (16.7) | 81.7 | 9 (6.5) | 1 (0.7)* |
Ceftazidime BMD | < 0.06- > 32 | 4 | > 32 | 106 (76.8) | 6 (4.3) | 26 (18.8) | – | – | – |
Ceftolozane-tazobactam GDM | 0.047- > 256 | 0.5 | 1.5 | 135 (97.8) | – | 3 (2.2) | 85.4 | 1 (0.7) | – |
Ceftolozane-tazobactam BMD | < 0.06- > 64 | 0.5 | 4 | 134 (97.1) | 1 (0.7) | 3 (2.2) | – | – | – |
Meropenem GDM | 0.023- > 32 | 4 | > 32 | 62 (44.9) | 20 (14.5) | 56 (40.6) | 92.9 | 6 (4.3) | – |
Meropenem BMD | < 0.06- > 32 | 4 | > 32 | 63 (45.7) | 20 (14.5) | 55 (39.9) | – | – | – |
Doripenem GDM | 0.004- > 32 | 4 | > 32 | 60 (43.5) | 25 (18.1) | 53 (38.4) | 89.6 | 8 (5.8) | 1 (0.7) |
Doripenem BMD | < 0.06- > 32 | 4 | 32 | 62 (44.9) | 25 (18.1) | 51 (37.0) | – | – | – |